

Baxter International Inc.
Key Product Line Sales
Period Ending September 30, 2003
(Unaudited)

(\$ in millions)	Q3 2003	Q3 2002	% Growth	YTD 2003	YTD 2002	% Growth
BioScience						
Recombinants	291	255	14%	788	734	7%
Plasma Proteins ¹	251	251	0%	710	730	(3%)
Antibody Therapy	77	83	(8%)	215	232	(8%)
Transfusion Therapies ²	133	130	3%	403	391	3%
Medication Delivery						
IV Therapies ³	275	244	13%	794	707	12%
Drug Delivery	175	147	19%	504	413	22%
Electronic Infusion Systems	181	168	8%	508	482	5%
Anesthesia ⁴	219	152	44%	638	435	47%
Renal						
PD Therapy	339	325	4%	977	929	5%
HD Therapy	107	106	1%	321	302	6%

¹ Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, biosurgery and other plasma-based products.

² Formerly referred to as Fenwal.

³ Principally includes intravenous solutions and nutritional products.

⁴ Includes ESI Lederle.